These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 35583791)

  • 41. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling pathway.
    Sun MF; Zhu YL; Zhou ZL; Jia XB; Xu YD; Yang Q; Cui C; Shen YQ
    Brain Behav Immun; 2018 May; 70():48-60. PubMed ID: 29471030
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Exploring the Connection Between the Gut Microbiome and Parkinson's Disease Symptom Progression and Pathology: Implications for Supplementary Treatment Options.
    Chan DG; Ventura K; Villeneuve A; Du Bois P; Holahan MR
    J Parkinsons Dis; 2022; 12(8):2339-2352. PubMed ID: 36278360
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis.
    Zhao Z; Ning J; Bao XQ; Shang M; Ma J; Li G; Zhang D
    Microbiome; 2021 Nov; 9(1):226. PubMed ID: 34784980
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Unravelling the role of gut microbiota in Parkinson's disease progression: Pathogenic and therapeutic implications.
    Rani L; Mondal AC
    Neurosci Res; 2021 Jul; 168():100-112. PubMed ID: 33417973
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Gut and Nonmotor Symptoms in Parkinson's Disease.
    Klingelhoefer L; Reichmann H
    Int Rev Neurobiol; 2017; 134():787-809. PubMed ID: 28805583
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A neuroscience perspective of the gut theory of Parkinson's disease.
    Smith LM; Parr-Brownlie LC
    Eur J Neurosci; 2019 Mar; 49(6):817-823. PubMed ID: 29446158
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease.
    Sampson TR; Debelius JW; Thron T; Janssen S; Shastri GG; Ilhan ZE; Challis C; Schretter CE; Rocha S; Gradinaru V; Chesselet MF; Keshavarzian A; Shannon KM; Krajmalnik-Brown R; Wittung-Stafshede P; Knight R; Mazmanian SK
    Cell; 2016 Dec; 167(6):1469-1480.e12. PubMed ID: 27912057
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Altered gut microbiota and intestinal permeability in Parkinson's disease: Pathological highlight to management.
    Sharma S; Awasthi A; Singh S
    Neurosci Lett; 2019 Nov; 712():134516. PubMed ID: 31560998
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Erythrocytic α-Synuclein and the Gut Microbiome: Kindling of the Gut-Brain Axis in Parkinson's Disease.
    Yang Y; Stewart T; Zhang C; Wang P; Xu Z; Jin J; Huang Y; Liu Z; Lan G; Liang X; Sheng L; Shi M; Cai Z; Zhang J
    Mov Disord; 2024 Jan; 39(1):40-52. PubMed ID: 37798868
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disease mechanisms as subtypes: Microbiome.
    Bonvegna S; Cilia R
    Handb Clin Neurol; 2023; 193():107-131. PubMed ID: 36803806
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Digesting recent findings: gut alpha-synuclein, microbiome changes in Parkinson's disease.
    Anis E; Xie A; Brundin L; Brundin P
    Trends Endocrinol Metab; 2022 Feb; 33(2):147-157. PubMed ID: 34949514
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emerging insights between gut microbiome dysbiosis and Parkinson's disease: Pathogenic and clinical relevance.
    Bi M; Feng L; He J; Liu C; Wang Y; Jiang H; Liu SJ
    Ageing Res Rev; 2022 Dec; 82():101759. PubMed ID: 36243356
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gut microbiome, short-chain fatty acids, alpha-synuclein, neuroinflammation, and ROS/RNS: Relevance to Parkinson's disease and therapeutic implications.
    Kalyanaraman B; Cheng G; Hardy M
    Redox Biol; 2024 May; 71():103092. PubMed ID: 38377788
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Microbiome, Parkinson's Disease and Molecular Mimicry.
    Miraglia F; Colla E
    Cells; 2019 Mar; 8(3):. PubMed ID: 30866550
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gut-oriented disease modifying therapy for Parkinson's disease.
    Lin CH; Lai HC; Wu MS
    J Formos Med Assoc; 2023 Jan; 122(1):9-18. PubMed ID: 36182642
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gut Microbiota Approach-A New Strategy to Treat Parkinson's Disease.
    Liu J; Xu F; Nie Z; Shao L
    Front Cell Infect Microbiol; 2020; 10():570658. PubMed ID: 33194809
    [TBL] [Abstract][Full Text] [Related]  

  • 57. What is the Evidence That Parkinson's Disease is a Prion Disorder, Which Originates in the Gut?
    Kujawska M; Jodynis-Liebert J
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30424585
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Link between Gut Dysbiosis and Neuroinflammation in Parkinson's Disease.
    Baizabal-Carvallo JF; Alonso-Juarez M
    Neuroscience; 2020 Apr; 432():160-173. PubMed ID: 32112917
    [TBL] [Abstract][Full Text] [Related]  

  • 59. From the Gut to the Brain: The Role of Enteric Glial Cells and Their Involvement in the Pathogenesis of Parkinson's Disease.
    Montalbán-Rodríguez A; Abalo R; López-Gómez L
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279293
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chronic stress-induced gut dysfunction exacerbates Parkinson's disease phenotype and pathology in a rotenone-induced mouse model of Parkinson's disease.
    Dodiya HB; Forsyth CB; Voigt RM; Engen PA; Patel J; Shaikh M; Green SJ; Naqib A; Roy A; Kordower JH; Pahan K; Shannon KM; Keshavarzian A
    Neurobiol Dis; 2020 Feb; 135():104352. PubMed ID: 30579705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.